Metal Ions in Biological Systems: Volume 42: Metal Complexes in Tumor Diagnosis and as Anticancer Agents

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

ISBN: 9780824754945 | 0824754948
Cover: Hardcover
Copyright: 3/26/2004

Rent

(Recommended)

$239.73

Term

Due

Price

Semester

Dec 13

$252.35

Quarter

Aug 16

$239.73

Short Term

Jul 6

$227.12

*This item is part of an exclusive publisher rental program and requires an additional convenience fee. This fee will be reflected in the shopping cart.
Buy New

Usually Ships in 3-5 Business Days

$344.77
eBook

Available Instantly

Online: 180 Days

Downloadable: 180 Days

$247.50

Volume 42 is devoted solely to the vital research area concerning metal complexes in cancer diagnosis and therapy and offers and authoritative and timely account by 29 internationally recognized experts. In 14 stimulating chapters, Metal Complexes in Tumor Diagnosis and as Anticancer Agents focuses on diagnostic tools such as magnetic resonance imaging (MRI), luminescent probes, and radiopharmaceuticals, including radiometallo-labeled peptides and assesses the role of metal ions, especially iron, in the action of antibiotics employed in anticancer chemotherapy.

PREFACE TO THE SERIES

iii

PREFACE TO VOLUME 42

CONTRIBUTORS

CONTENTS OF PREVIOUS VOLUMES

xix

HANDBOOK ON TOXICITY OF INORGANIC COMPOUNDS

liv

HANDBOOK ON METALS IN CLINICAL AND ANALYTICAL CHEMISTRY

liv

HANDBOOK ON METALLOPROTEINS

liv

Chapter 1 MAGNETIC RESONANCE CONTRAST AGENTS FOR MEDICAL AND MOLECULAR IMAGING

(38)

Matthew J. Allen and Thomas J. Meade

1. Introduction

(3)

2. Contrast Agents for Diagnosis

(6)

3. Targeted Delivery of Contrast Agents

(3)

4. Imaging Biochemical Events

(12)

5. Conclusions and Outlook

(1)

Acknowledgments

(1)

Abbreviations

(2)

References

(11)

Chapter 2 LUMINESCENT LANTHANIDE PROBES AS DIAGNOSTIC AND THERAPEUTIC TOOLS

(38)

Jean-Claude G. Bünzli

1. Lanthanide-Based Luminescent Probes: Why?

(4)

2. Designing a Lanthanide-Based Luminescent Probe

(13)

3. Applications in Medical Diagnosis

(8)

4. Use of Lanthanide Complexes in Photodynamic Therapies

(5)

5. Concluding Remarks

(1)

Acknowledgments

(1)

Abbreviations

(1)

References

(5)

Chapter 3 RADIOLANTHANIDES IN NUCLEAR MEDICINE

(32)

Frank Rösch and Eva Forssell-Aronsson

1. Introduction

(1)

2. Radiolanthanide Production

(3)

3. Labelling Chemistry and Labelled Compounds

(2)

4. Application of Radiolanthanide Radiopharmaceuticals

(15)

5. Conclusion

(1)

Abbreviations

100

(1)

References

101

(8)

Chapter 4 RADIOMETALLO-LABELED PEPTIDES IN TUMOR DIAGNOSIS AND THERAPY

109

(34)

Mihaela Ginj and Helmut R. Maecke

1. Introduction

110

(6)

2. Radiometals of Interest for Peptide Labeling and Labeling Approaches

116

(8)

3. In Vitro Characterization of Radiometallo-Peptides

124

(4)

4. Animal Models to Study Targeting of Tumors. Biodistribution Therapy Studies

128

(2)

5. Influence of the (Radio)Metal Ion and Its Coordination Chemistry on the Targeting Properties of Radiometallo-Peptides

130

(3)

6. Overview of Patient Studies

133

(4)

7. Summary and Conclusion

137

(1)

Abbreviations

137

(2)

References

139

(4)

Chapter 5 CISPLATIN AND RELATED ANTICANCER DRUGS: RECENT ADVANCES AND INSIGHTS

143

(36)

Katie R. Barnes and Stephen J. Lippard

1. Introduction

144

(1)

2. Mechanism of Action

145

(15)

3. Cellular Defenses Against Cisplatin

160

(3)

4. Novel Cisplatinum Analogs as Anticancer Compounds

163

(4)

5. Conclusions and Future Directions

167

(1)

Acknowledgment

168

(1)

Abbreviations

168

(1)

References

169

(10)

Chapter 6 THE EFFECT OF CYTOPROTECTIVE AGENTS IN PLATINUM ANTICANCER THERAPY

179

(30)

Michael A. Jakupec, Markus Galanski, and Bernhard K. Keppler

1. Toxicity Associated with Platinum Anticancer Therapy

179

(4)

2. Overview of Cytoprotective Approaches

183

(3)

3. Amifostine

186

(4)

4. Glutathione

190

(4)

5. BNP7787 (Dimesna)

194

(1)

6. α-Tocopherol (Vitamin E)

195

(1)

7. α-Lipoic Acid

196

(1)

8. Concluding Remarks

196

(2)

Abbreviations

198

(1)

References

198

(11)

Chapter 7 ANTITUMOR ACTIVE TRANS-PLATINUM COMPOUNDS

209

(42)

Giovanni Natile and Mauro Coluccia

1. Introduction

210

(11)

2. Antitumor Active Trans-Platinum Compounds

221

(18)

3. Conclusions and Perspectives

239

(2)

Acknowledgments

241

(1)

Abbreviations and Definitions

241

(1)

References

242

(9)

Chapter 8 POLYIUCLEAR PLATINUM DRUGS

251

(46)

Nicholas Farrell

1. Introduction

252

(1)

2. Structural Variations within Polynuclear Platinum Complexes

253

(8)

3. DNA Binding Modes of Polynuclear Platinum Drugs

261

(13)

4. Trifunctional Dinuclear Platinum Complexes. Ternary DNA-Protein Crosslinking

274

(3)

5. Polynuclear Platinum Complexes Bind Faster to Single-Stranded DNA

277

(5)

6. Biological Activity of Polynuclear Platinum Compounds

282

(5)

7. Clinical Experience

287

(1)

8. Conclusions

288

(1)

Acknowledgments

289

(1)

Abbreviations

290

(1)

References

290

(7)

Chapter 9 PLATINUM(IV) ANTICANCER COMPLEXES

297

(26)

Matthew D. Hall, Rachael C. Dolman, and Trevor W. Hambley

1. Introduction

298

(1)

2. History

298

(2)

3. Mechanism of Action

300

(1)

4. Design

301

(6)

5. Synthesis

307

(3)

6. In Vitro Interactions with Biomolecules

310

(1)

7. Biological Fate

311

(5)

8. Conclusions

316

(1)

Acknowledgments

316

(1)

Abbreviations

316

(1)

References

317

(6)

Chapter 10 RUTHENIUM ANTICANCER DRUGS

323

(30)

Enzo Alessio, Giovanni Mestroni, Alberta Bergamo, and Gianni Sava

1. Introduction

324

(1)

2. Chemical Features

325

(9)

3. Pharmacological Control of Tumor Growth

334

(10)

4. Conclusions

344

(2)

Acknowledgments

346

(1)

Abbreviations

346

(1)

References

347

(6)

Chapter 11 ANTITUMOR TITANIUM COMPOUNDS AND RELATED METALLOCENES

353

(32)

Francesco Caruso and Miriam Rossi

1. Introduction

354

(4)

2. Evolution of Titanium Drugs in Physiological Medium

358

(2)

3. Potential Targets

360

(2)

4. Attachment to Carriers

362

(1)

5. Structure-Activity Studies

362

(6)

6. Phase II Clinical Trials of Titanocene Dichloride

368

(1)

7. Non-Titanium Metallocenes

369

(7)

8. Conclusions Regarding Titanium-Based Antitumor Drugs

376

(2)

Acknowledgments

378

(1)

Abbreviations and Definitions

378

(1)

References

379

(6)

Chapter 12 GOLD COMPLEXES AS ANTITUMOR AGENTS

385

(40)

Luigi Messori and Giordana Marcon

1. Introduction

386

(2)

2. Main Chemical Features of Gold Complexes

388

(2)

3. Gold(I) Complexes as Antitumor Agents

390

(9)

4. Gold(III) Complexes as Antitumor Agents

399

(20)

5. Conclusions and Perspectives

419

(1)

Acknowledgments

420

(1)

Abbreviations

420

(1)

References

421

(4)

Chapter 13 GALLIUM AND OTHER MAIN GROUP METAL COMPOUNDS AS ANTITUMOR AGENTS

425

(38)

Michael A. Jakupec and Bernhard K. Keppler

1. Introduction

426

(1)

2. "Simple Gallium Salts"

427

(14)

3. Gallium Complexes

441

(7)

4. Other Main Group Metal Compounds in Cancer Therapy

448

(1)

5. Summary and Conclusions

449

(2)

Abbreviations

451

(1)

References

451

(12)

Chapter 14 METAL ION DEPENDENT ANTIBIOTICS IN CHEMOTHERAPY

463

(36)

David H. Petering, Chuanwu Xia, and William E. Antholine

1. Introduction

464

(4)

2. Direct Requirements of Antibiotics for Metal Ions: Mechanism of Action of Bleomycin

468

(10)

3. Indirect Requirements of Antibiotics for Metal Ions: Mechanism of Action of Doxorubicin

478

(7)

4. Survey of Metal-Linked Antibiotics

485

(3)

5. Discussion

488

(1)

Acknowledgments

488

(1)

Abbreviations and Definitions

488

(1)

References

489

(10)

SUBJECT INDEX

499

Please wait while the item is added to your bag...

FREE SHIPPING

Amazon no longer offers textbook rentals. We do!

Metal Ions in Biological Systems: Volume 42: Metal Complexes in Tumor Diagnosis and as Anticancer Agents

Summary

Table of Contents

Supplemental Materials